rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    VKTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Viking: 3 Key Takeaways for Long-Term Investors
      Nov 17Yahoo FinanceVKTX
      Why Did Viking Therapeutics Stock Jump?
      Nov 16Yahoo FinanceVKTX
      Viking Therapeutics (VKTX) Heads To Two Conferences, Is The Discount To Analyst Targets Warranted?
      Nov 12Yahoo FinanceVKTX
      Is Viking Therapeutics (VKTX) Priced For Perfection After ObesityWeek?

      Viking Therapeutics has delivered very strong long term share returns, and that kind of history can leave investors wondering whether the current US$28.44 price still lines up with what its balance sheet says the business is worth. With the spotlight on Viking Therapeutics as it pushes ahead in obesity drug development, the open question is how far the market price has moved relative to its book value. Over the past 5 years, Viking Therapeutics has returned about 391.2%, which raises the...

      Nov 12Yahoo FinanceVKTX
      Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner? | The Motley Fool

      These drugmakers offer very different risk-reward profiles.

      Nov 11The Motley FoolVKTXLLY
      Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
      Nov 9MorningstarVKTX
      Here's the 1 Stock I'd Most Want to Buy If the Market Crashes
      Nov 5Yahoo FinanceVKTX
      Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors. | The Motley Fool

      Viking aims to enter the weight loss drug market.

      Nov 4The Motley FoolVKTX
      Viking Therapeutics to Participate at Upcoming Investor Conferences
      Nov 3MorningstarVKTX
      UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case. | The Motley Fool

      Trial results for its weight loss drugs could justify a higher valuation for the clinical-stage biotech.

      Nov 2The Motley FoolVKTXUBS
      Viking Therapeutics: A Strong Injection, A Scaled-Back Pill (NASDAQ:VKTX)
      Oct 31Seeking AlphaVKTX
      VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?
      Oct 30Yahoo FinanceVKTX
      Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

      Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

      Oct 30Yahoo FinanceVKTX
      Viking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet) (VKTX)
      Oct 29Seeking AlphaVKTX
      VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses

      Detailed price information for Viking Thera (VKTX-Q) from The Globe and Mail including charting and trades.

      Oct 29The Globe and MailVKTX
      Viking Therapeutics Stock Jumps: What's Going On?
      Oct 29BenzingaVKTX
      Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases
      Oct 29Yahoo FinanceVKTXLLYNVO
      VKTX Q3 Earnings Call Highlights Obesity Pipeline Progress
      Oct 29Yahoo FinanceVKTX
      Viking Therapeutics, Inc. Q3 2026 Earnings Call Summary

      Moby summary of Viking Therapeutics, Inc.'s Q3 2026 earnings call

      Oct 29Yahoo FinanceVKTX
      Viking Therapeutics: Why A Successful Maintenance Readout Couldn't Save The Stock (VKTX)

      Viking Therapeutics faces dilution risk, rising costs, and tough obesity drug competition. Read here for a detailed analysis of VKTX stock.

      Oct 29Seeking AlphaVKTX
      Viking Therapeutics (VKTX) Posted Wider Losses, Is The Stock Overvalued?
      Oct 29Yahoo FinanceVKTX
      Viking Therapeutics Q3 Earnings Call Highlights
      Oct 29Yahoo FinanceVKTX
      Viking (VKTX) Q3 2026 Earnings Call Transcript
      Oct 29The Globe and MailVKTX
      VKTX Stock Slides Overnight After Q3 Loss: CEO’s Obesity Drug Launch Timeline Frustrates Retail
      Oct 29Yahoo FinanceVKTX
      Earnings call transcript: Viking Therapeutics Q3 2026 loss widens on higher R&D
      Oct 28Investing.comVKTX
      Viking Therapeutics falls on third quarter loss miss
      Oct 28Investing.comVKTX
      Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
      Oct 28Yahoo FinanceVKTX
      Viking Therapeutics earnings up next: Obesity drug progress in focus
      Oct 28Investing.comVKTX
      Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market
      Oct 23Yahoo FinanceVKTX
      Viking Therapeutics stock hits 52-week low at 24.94 USD
      Oct 23Investing.comVKTX
      Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
      Oct 22Yahoo FinanceVKTX
      NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains?
      Oct 22Yahoo FinanceVKTXNVO
      Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
      Oct 21MorningstarVKTX
      The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics

      BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics advance late-stage drug pipelines, with key regulatory decisions and clinical trial results ahead.

      Oct 21Yahoo FinanceVKTX
      Viking Therapeutics (VKTX) Stock Looks Overvalued Next To Its Book Value
      Oct 20Yahoo FinanceVKTX
      Viking Therapeutics Stock What SUNRISE Phase 3 Start Means For VK2735
      Oct 20Yahoo FinanceVKTX
      Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2 | The Motley Fool

      Nothing is certain in clinical trials, but investors have reason to expect a better outcome in the oral VK2735 trials.

      Oct 20The Motley FoolVKTX
      Can Viking Therapeutics Carve Out a Place in the Obesity Market?
      Oct 20Yahoo FinanceVKTX
      Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter. | The Motley Fool

      Viking Therapeutics raised $575 million to fund major obesity drug trials, develop its pipeline, and support commercial development of any approvals for VK2735.

      Oct 18The Motley FoolVKTX
      Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
      Oct 16Yahoo FinanceVKTX
      Viking Therapeutics Starts Phase III Development of Obesity Pill
      Oct 15Yahoo FinanceVKTX
      Viking Therapeutics stock hits 52-week low at 25.77 USD
      Oct 14Investing.comVKTX
      Viking’s Key Obesity Pill Enters Phase 3 Trial – Here’s What Investors Need To Know
      Oct 14Yahoo FinanceVKTX
      Viking Therapeutics launches phase 3 trials for oral obesity drug
      Oct 14Investing.comVKTX
      Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
      Oct 14Yahoo FinanceVKTX
      Viking Therapeutics (VKTX) Stock Dropped, So What Is Driving Attention Now?
      Oct 14Yahoo FinanceVKTX
      10 Health Care Stocks With Whale Alerts In Today’s Session - Viking Therapeutics (NASDAQ:VKTX), Thermo Fi

      This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

      Oct 13BenzingaVKTX
      2 Stocks That Could Soar in Q4 | The Motley Fool

      These growth companies offer investors the potential for near-term upside from fourth-quarter catalysts and long-term growth from realizing value in their pipelines.

      Oct 12The Motley FoolVKTX
      Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call. | The Motley Fool

      Oppenheimer raised Viking Therapeutics' price target to $120, citing strong trial data, and an improving probability of success for its key drug.

      Oct 12The Motley FoolVKTXOPY
      Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?
      Oct 10Yahoo FinanceVKTX

      This is the newest page. Registered accounts read further back.